Mankind Pharma has struck a deal to acquire the women’s-health portfolio of its subsidiary Bharat Serums & Vaccines (BSV) for ₹797 crore, positioning itself for growth in fertility, gynaecology and post-pregnancy segments.
Glimpse:
Mankind Pharma has entered into a business transfer agreement with its subsidiary BSV to acquire the latter’s women-health portfolio for approximately ₹797 crore. The move strategically expands Mankind’s presence in the women’s health segment and complements its existing strengths in reproductive health.
Mankind Pharma has announced the acquisition of BSV’s women’s health portfolio for ₹797 crore, in a move designed to strengthen its footprint in the growing women’s healthcare market in India. Under the agreement, the business transfer will move key brands and assets focused on gynaecology, fertility solutions, and post-pregnancy care from BSV into Mankind’s operations.
The acquisition is aligned with Mankind’s broader strategy to diversify and deepen its presence beyond general formulations into higher-growth specialty segments. Women’s health is seen as a segment with robust demand, both from demographic trends and rising healthcare awareness. By internalising the portfolio, Mankind expects to drive brand synergies, expand its reach into underserved regions, and leverage its existing distribution infrastructure.
This step also reflects wider consolidation in the Indian pharmaceutical sector, where companies are increasingly aligning with niche growth areas and building targeted portfolios rather than relying solely on volume generics. For BSV, the transfer allows focus to sharpen on its key vaccine and speciality biologics operations, while the women’s health lines gain scale and backing from Mankind’s commercial engine.
While the deal value is significant at ₹797 crore, execution will determine how effectively Mankind integrates the acquired brands, manages regulatory and product lifecycle complexity, and expands market share in a competitive segment. The transaction sends a signal that women’s-health therapies remain a strategic priority for Indian pharma players as they chase higher value segments and specialty care growth.
“This acquisition strongly positions us for leadership in the women’s health space, enabling us to combine brand heritage, commercial reach and therapeutic depth.”
By
HB Team
